Spots Global Cancer Trial Database for Selinexor, Pomalidomide, and Dexamethasone For Multiple Myeloma With CNS Involvement

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Trial Identification

Brief Title: Selinexor, Pomalidomide, and Dexamethasone For Multiple Myeloma With CNS Involvement

Official Title: A Phase 2 Study of Selinexor, Pomalidomide, and Dexamethasone For Multiple Myeloma With Central Nervous System Involvement

Study ID: NCT05478993

Conditions

Multiple Myeloma

Interventions

SPD：Selinexor Oral Tablet, Pomalidomide, Dexamethasone

Study Description

Brief Summary: This is a single-arm, open-label, multicenter, exploratory study initiated by investigator to evaluate the efficacy and safety of Selinexor (S) combined with pomalidomide (P) and dexamethasone (D) in the treatment of multiple myeloma with CNS involvement.

Detailed Description: This is a single-arm, open-label, multicenter, exploratory study. The study plans to enroll patients diagnosed with multiple myeloma with CNS involvement to receive Selinexor (60 mg QW), pomalidomide (4 mg/day, on Days 1-21), and dexamethasone (40 mg/day, on Days 1, 8, 15, 22), with all agents dosed 28 days per cycle. If patients reach maximum efficacy and have received SPD treatment for 8-12 cycles, maintenance treatment of Selinexor (20-60mg QW, optimal dose determined by the investigator) will be started and continued until disease progression or intolerable adverse events.